Report
Luis Arredondo
EUR 50.00 For Business Accounts Only

ROVI: MODERNA ANNOUNCES DELAYS IN VACCINE DELIVERIES (ANÁLISIS BANCO SABADELL)

In its 3Q’22 earnings presentation, Moderna announced that it expects between US$ 18 Bn and US$ 19 Bn in revenues from Advanced Purchase Agreements, meaning that certain deliveries, totalling around US$ 2 Bn/US$ 3 Bn, will be put off to 2023 due to short-term supply constraints.
Underlying
Laboratorios Farmaceuticos Rovi S.A.

Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.

Provider
Sabadell
Sabadell

Analysts
Luis Arredondo

Other Reports on these Companies
Other Reports from Sabadell

ResearchPool Subscriptions

Get the most out of your insights

Get in touch